rs2811712 — CDKN2BAS

Regulatory variant in the ANRIL long non-coding RNA at the 9p21.3 locus that influences CDKN2B expression and functional aging; the G allele is protective against physical impairment with age

See your personal result for CDKN2BAS

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ANRIL and Functional Aging — The 9p21.3 Longevity Locus

A single stretch of chromosome 9 — the 9p21.3 locus — is the most consistently replicated region in genome-wide association studies for age-related disease. Coronary artery disease, type 2 diabetes, glioma, melanoma, and now physical aging have all been linked to variation here. At the heart of the locus sits ANRIL (antisense non-coding RNA in the INK4 locus)11 ANRIL (antisense non-coding RNA in the INK4 locus)
Also designated CDKN2BAS or CDKN2B-AS1 — a long non-coding RNA transcribed antisense to the CDKN2A/CDKN2B tumor suppressor genes, a molecular rheostat for cellular senescence.

rs2811712 is a tag SNP within ANRIL that was identified in a landmark study as associated with physical function in older people22 associated with physical function in older people
Melzer D et al. A common variant of the p16INK4a genetic region is associated with physical function in older people. Mech Ageing Dev. 2007. The G allele — carried by roughly one in five people of European ancestry — is associated with substantially better preserved physical function in old age, while the common A allele is the risk-conferring genotype.

The Mechanism

The 9p21.3 locus contains three protein-coding genes — CDKN2A (encoding p16INK4a and p14ARF), CDKN2B (encoding p15INK4b), and MTAP — all flanked and overlapped by ANRIL. p16INK4a and p15INK4b are cyclin-dependent kinase inhibitors33 cyclin-dependent kinase inhibitors
CDK inhibitors block CDK4/6, preventing phosphorylation of Rb and halting cell-cycle progression from G1 to S phase — the canonical senescence checkpoint that drive cellular senescence: as cells age and accumulate damage, p16 levels rise, arresting the cell cycle and converting cells into senescent "zombie" cells44 senescent "zombie" cells
Senescent cells stop dividing but remain metabolically active, secreting pro-inflammatory cytokines (the SASP — senescence-associated secretory phenotype) that damage neighboring tissue that fuel the chronic inflammation underlying age-related functional decline.

ANRIL regulates CDKN2A/CDKN2B expression in cis through Polycomb group protein recruitment, particularly the PRC2 complex, which methylates histone H3K27 to silence the INK4 locus. In proliferating cells, ANRIL keeps senescence genes suppressed; as ANRIL expression shifts with aging or genetic variation, the balance tips toward elevated p16 and p15, accelerating the senescent phenotype.

The Evidence

The primary association was established by Melzer et al. (2007)55 Melzer et al. (2007)
A common variant of the p16INK4a genetic region is associated with physical function in older people. Mechanisms of Ageing and Development. across three independent European cohorts totaling 3,372 elderly individuals (EPIC-Norfolk sets 1 and 2 plus InCHIANTI). Severely limited physical function was present in 15.0% of AA homozygotes versus 7.0% of GG homozygotes, nearly half the rate. The per-A-allele odds ratio was 1.48 (95% CI 1.17–1.88, p = 0.001), adjusted for age, sex, and study. The association held across all three cohorts tested independently, including a trend in the Iowa-EPESE cohort (n=419, p=0.079 one-sided), making this one of the first robust genetic associations for functional aging specifically.

A Han Chinese case-control study Wu et al. (2012)66 Wu et al. (2012)
Heterozygote genotypes at rs2222823 and rs2811712 SNP loci are associated with cerebral small vessel disease in Han Chinese population found the heterozygote genotype at rs2811712 was associated with OR 1.75 (CI 1.13–2.71, p=0.004) for cerebral small vessel disease.

The broader 9p21.3 locus literature confirms that ANRIL variants influence CDKN2B expression and cellular senescence77 CDKN2B expression and cellular senescence
SNPs here show inverse effects on ANRIL and CDKN2B expression, supporting a role of antisense transcription in regulating senescence pathways, with the risk alleles generally increasing ANRIL expression in ways that paradoxically reduce appropriate p16/p15 upregulation in vascular cells, impairing the normal senescence response to damage. This locus is the strongest genetic signal for coronary artery disease in Europeans (OR ~1.3 per risk allele), though rs2811712 itself does not independently associate with CAD — its primary documented phenotype is functional physical aging.

Practical Actions

For carriers of two A alleles (AA), the evidence supports a targeted approach to slowing the accumulation of senescent cells and their inflammatory secretome. The most directly relevant interventions for the CDKN2B/p16 axis include:

  • Senolytic compounds: Fisetin (a flavonoid concentrated in strawberries and onions) and quercetin have demonstrated senolytic activity in human studies — selectively promoting apoptosis in p16-expressing senescent cells. Intermittent high-dose fisetin (≥500 mg/day for 2–3 days per month) reduced senescent cell burden and SASP markers in published clinical data.
  • Strength and resistance training: p16-driven muscle senescence contributes directly to sarcopenia (age-related muscle loss) — the leading mediator of physical impairment in older adults. Resistance training specifically reduces senescent cell burden in skeletal muscle and preserves muscle fiber function through mechanisms that parallel the CDKN2B pathway.

AG carriers carry one protective G allele: physical function risk is intermediate, and the same principles apply with moderated urgency.

Interactions

rs564398 (upstream of CDKN2A): Another 9p21 tag SNP associated with type 2 diabetes and glioma risk, which shares the ANRIL regulatory context. Combined risk at rs2811712 and rs564398 may implicate broader ANRIL dysregulation beyond the physical aging phenotype.

Genotype Interpretations

What each possible genotype means for this variant.

GG Protective Genotype Beneficial

Two protective G alleles — substantially reduced functional aging risk

The GG genotype at rs2811712 represents the most favorable common variant state at this ANRIL regulatory locus. The association replicated across EPIC-Norfolk and InCHIANTI with consistent direction and magnitude.

This protective signal does not eliminate aging-related risk — lifestyle, fitness, cardiovascular risk factors, and other genetic variants all contribute — but it does indicate a meaningful genetic tailwind for physical function in later decades.

AG Partial Protection Intermediate

One protective G allele — intermediate functional aging risk

The G allele at rs2811712 appears to confer a dosage-dependent protective effect on physical function in aging. The additive inheritance pattern documented in the study (per-allele OR 1.48) means one allele confers roughly the square root of the two-allele protective benefit.

Your one G allele is meaningful — the risk increment above the GG baseline is approximately half what AA carriers face. Preventive strategies remain important, particularly as you age past 60 when senescent cell burden rises steeply.

AA Common Genotype High Risk

Increased susceptibility to age-related physical impairment

The 9p21.3 locus where rs2811712 sits is one of the most studied regions in human genetics, linking ANRIL expression to the cyclin-dependent kinase inhibitors p16INK4a and p15INK4b. These proteins enforce cell cycle arrest in damaged cells — a necessary safeguard against cancer, but one that accelerates tissue aging when too many cells become senescent.

The association with physical function was replicated across three independent European cohorts (EPIC-Norfolk sets 1 and 2, InCHIANTI).

No intervention can eliminate genetic risk, but senescent cell burden is a modifiable biological target. Senolytic compounds and resistance training are the most evidence-grounded strategies for this specific locus.